The Lanka Hospitals Corporation PLC Financial Summary and Investment Analysis

Executive Overview

The Lanka Hospitals Corporation PLC is a Sri Lankan private healthcare group centred on hospital operations, diagnostics, pharmacy services and healthcare education. Its 2025 audited results were the strongest reported to date, with revenue of Rs.14.474 Bn, profit after tax of Rs.1.944 Bn and EPS of Rs.8.69. Momentum strengthened into 2026: H1 2026 revenue increased 9.4% YoY and PAT 55.4%, although operating cash generation weakened sharply because of working-capital absorption and higher capital expenditure.

The balance sheet remains unusually strong, with management describing a zero-leverage structure, substantial financial investments, high liquidity and equity equal to 77% of assets at 2026-06-30.

Periods covered: Q3 2023-Q2 2026, audited CY2023-CY2025 historical information, and market information through 2026-08-14. CY2025 is audited; Q1-Q2 2026 figures are provisional and unaudited.

Financial Performance

Revenue and Profitability Trends

*Rs. Mn; quarterly figures are provisional figures reported for each three-month period.*

Quarterly revenue has moved from roughly Rs.3.1 Bn in Q3 2023 to Rs.3.8 Bn in Q2 2026. Q2 2026 revenue grew 7.0% YoY, gross profit 10.1%, and PAT 60.2%. However, operating profit declined 10.7% YoY to Rs.398.8 Mn as administrative and other operating expenses rose.

The major Q2 earnings accelerator was finance income of Rs.508.1 Mn, versus Rs.206.3 Mn in Q2 2025.

For H1 2026, revenue was Rs.7.598 Bn (+9.4%), gross profit Rs.3.404 Bn (+15.3%), operating profit Rs.832.0 Mn (+10.1%), PBT Rs.1.577 Bn (+37.0%) and PAT Rs.1.223 Bn (+55.4%). Net margin expanded from 11.3% to 16.1%.

For audited CY2025, revenue rose 6% to Rs.14.474 Bn, gross profit 8% to Rs.6.411 Bn and PAT 45% to Rs.1.944 Bn. Revenue and PAT CAGRs from CY2023-CY2025 were approximately 8.0% and 20.2%, respectively.

Finance income remains an important earnings variable. CY2025 finance income surged to Rs.920.4 Mn from Rs.244.2 Mn, including a Rs.274.8 Mn foreign-currency translation gain, versus a Rs.433.9 Mn loss in 2024.

Balance Sheet Analysis

At 2026-06-30, equity represented 77.1% of assets. Other financial assets alone were Rs.10.097 Bn, while cash and cash equivalents were Rs.1.015 Bn.

A notable development is inventories rising from Rs.978.0 Mn at 2025-12-31 to Rs.1.361 Bn, a 39% increase. Total liabilities nevertheless fell from Rs.5.040 Bn to Rs.4.875 Bn while equity increased 6.5%.

The Group reports gearing as N/A and management explicitly describes the balance sheet as zero-debt, although lease liabilities and bank overdrafts remain.

Cash Flow Analysis

*Free cash flow calculated as operating cash flow less PPE, capital-work and intangible expenditure where reported.*

Despite strong H1 2026 earnings, operating cash flow fell 57.6% YoY. The main drag was working capital, particularly the Rs.394.0 Mn inventory build, compared with only Rs.8.5 Mn in H1 2025. H1 2026 also included Rs.574.7 Mn of PPE purchases and Rs.671.2 Mn of dividends paid, producing a Rs.340.0 Mn decline in net cash equivalents.

Thus, the key short-term financial issue is not profitability but cash conversion.

Key Financial Ratios and Growth Indicators

Audited CY2025 ROA was 10%, ROCE 11%, operating margin 14%, net margin 13%, EPS Rs.8.69 and NAVPS Rs.68.72. At the 2025 closing price of Rs.106.00, the reported P/E was 12.20x, dividend yield 3% and payout ratio 40%.

Operationally, hospital revenue increased 6% in 2025, supported by 5% inpatient and 2% outpatient volume growth. Diagnostics revenue increased 13% and test volumes 8%, while pharmacy revenue declined 4%, partly from regulatory price controls.

Diagnostics remains the only CAP-accredited laboratory in Sri Lanka, with accreditation renewed through April 2027. Six company-owned collection centres were added in 2025.

Economic and Market Context

Management described 2025 as a period of improving Sri Lankan macroeconomic stability, recovering disposable incomes, lower inflation and more predictable interest rates. These conditions supported healthcare demand.

Against this, the healthcare inflation sub-index increased 5.4%, imported medical inputs remain exposed to exchange rates, and competition for specialised clinical staff continues.

Structural demand drivers include an ageing population, chronic diseases, growing health awareness, preventive care, specialised treatment and potential medical tourism.

Future Potential and Outlook

Management's strategy through 2030 emphasises patient-centred and preventive healthcare, digital transformation, specialised medicine and revenue diversification.

Key initiatives include a dedicated robotic surgery unit, laboratory automation, integrated HIS/LIS/EMR systems, AI-assisted diagnostics, predictive analytics, paperless operations, additional channelling rooms and expanded medical tourism.

The Hospital reported a 35% increase in cardiac surgeries, completed 86 bariatric surgeries in 2025 and added a third cardiothoracic operating theatre. Diagnostics plans additional geographic and specialised-test expansion. Pharmacy intends larger flagship locations and a medical centre/pharmacy at Cinnamon Life.

Risks and Challenges

Major risks identified by management include clinical/patient-safety failures, skilled-worker shortages, macroeconomic and exchange-rate volatility, intense private-healthcare competition, regulatory changes, cybersecurity, reputational damage and climate-related disruption.

Skills availability and cybersecurity are rated high-impact/high-likelihood risks. Competition may pressure pricing and margins, while specialised talent shortages can constrain expansion.

A further financial risk is increasing dependence on finance income and foreign-exchange movements for incremental profit growth. H1 2026's weaker cash conversion despite strong reported earnings also warrants monitoring.

Shareholder and Corporate Information

At 2026-06-30, Fortis Healthcare International Pte Ltd held 28.66%, Sri Lanka Insurance Corporation Life Fund 26.27%, General Fund 25.07%, and Property Development PLC 9.53%; these four collectively control approximately 89.5%.

Public holding remained 20%, with 44,749,303 public shares and 7,885 public shareholders. Institutional investors held 95.54% of total shares. Directors reported no material holdings; the Group Chief Executive Officer held 600 shares.

The share closed at Rs.112.25 on 2026-08-14, versus Rs.102.00 on 2026-04-02, a 90-session return of 10.05%. The observed range was Rs.99.60-Rs.128.50.

Investment Decision Indicators

Strengths: sustained revenue growth; rapidly improving profitability; 44%-45% gross margins; very strong liquidity and equity funding; effectively debt-free capital structure; leading clinical/diagnostic positioning; expanding specialised healthcare; rising NAVPS; strong dividend capacity.

Weaknesses: H1 2026 cash conversion deteriorated materially; inventories increased sharply; operating expenses continue to rise; quarterly earnings are significantly influenced by finance/FX income; pharmacy growth is currently weak.

Opportunities: medical tourism, robotic and specialised surgery, diagnostics expansion, AI/digital healthcare, preventive care, laboratory automation, new capacity and pharmacy formats.

Threats: skilled-worker shortages, cybersecurity, healthcare regulation, competition, currency movements, imported-input costs, clinical/reputation risks and weaker consumer affordability.

Overall assessment: The reports depict a financially strong healthcare group transitioning from a steady-growth hospital operator toward a broader technology-enabled and specialised healthcare platform. Core operating performance is improving, but the unusually strong recent bottom-line growth partly reflects finance and foreign-exchange income. The most important indicators to monitor are operating-margin progression, finance-income contribution, H2 2026 working-capital normalisation, free cash flow, inventory levels and returns from the planned capital expansion. No BUY/SELL/HOLD conclusion is implied; these metrics determine whether recent earnings growth proves structurally sustainable.